The partnership is poised to increase patient impact, especially for those who would benefit from enhanced care co-ordination ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

Regeneron Pharmaceuticals has announced that it will be acquiring human genetics and biotechnology company 23andMe for $256m.

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

Yancopoulos, M.D. Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron. “We have deep experience with large-scale data management, having worked with ...

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution for improving the management of chronic obstructive ...